Abstract:We have previously found, in striatal membrane preparations from young (2 months old) rats, that stimulation of adenosine A2 receptors (with the selective adenosine A2 agonist CGS 21680) increases the dissociation constants of high- (Kh) and low-affinity (Kl) dopamine D2 binding sites (labelled with the selective dopamine D2 antagonist [3H]raclopride) without changing the proportion of high affinity binding sites (Rh). In the present study in striatal preparations from adult (6 months old) rats, it was found that in addition to the increase in both Kh and Kl values, stimulation of adenosine A2 receptors is associated with an increase in Rh. These result suggest that, in the adult rat, adenosine A2 stimulation may inhibit the behavioural effects induced by dopamine D2 stimulation both by decreasing the affinity and the transduction of dopamine D2 receptors. We have also studied the intramembrane A2-D2 receptor interaction in an experimental model of Parkinson's disease, namely in rats with a unilateral 6-OH-dopamine-induced lesion of the nigro-striatal dopamine pathway. It was found that a unilateral dopamine denervation is associated with a higher density of striatal dopamine D2 receptors in the order of 20%, without any change in their affinity compared with the unlesioned neostriatum. Furthermore, the density (Bmax values) of dopamine D2 receptors in the contralateral neostriatum was significantly higher (about 20%) than in the striatum from native animals. This finding suggests that an unilateral dopamine denervation also induces compensatory long-lasting changes of dopamine D2 receptors in the contralateral neostriatum. In addition to the hightened sensitivity to dopamine agonists, it is known that the dopamine denervated striatum is more sensitive to adenosine antagonists like methylxanthines. If the adenosine A2-dopamine D2 interaction is the main mechanism of action mediating the central effects of methylxanthines, the dopamine denervation might also potentiate this interaction, i.e., dopamine D2 receptors could be not only more sensitive to dopamine but also to adenosine A2 receptor activation. Our results support this hypothesis, since membrane preparations from the denervated neostriatum are more sensitive to the effect of CGS 21680 on dopamine D2 receptors. Thus a low dose of CGS 21680 (3 nM), which is not effective in membrane preparations from the neostriatum of naive animals, is still effective in membranes from the denervated neostriatum. These results underline the potential antiparkinsonian activity of adenosine A2 antagonists.

Boolean analysis shows a high proportion of dopamine D2 receptors interacting with adenosine A2A receptors in striatal medium spiny neurons of mouse and non-human primate models of Parkinson's disease

Dopamine heteroreceptor complexes as therapeutic targets in Parkinson’s disease

Dopamine Denervation Leads to an Increase in the Intramembrane Interaction Between Adenosine A2 and Dopamine D2 Receptors in the Neostriatum

Adenosine A2A receptors in Parkinson’s disease treatment

Dopaminergic Pharmacology Revealed by Structures of Human Dopamine D3 Receptor-G I Complexes

L-DOPA Treatment Modulates Nicotinic Receptors in Monkey Striatum.

Discovery of Novel Dual Adenosine A1/A2A Receptor Antagonists Using Deep Learning, Pharmacophore Modeling and Molecular Docking.

Discovery of Novel and Selective Adenosine A2A Receptor Antagonists for Treating Parkinson's Disease Through Comparative Structure-Based Virtual Screening

Dopamine–endocannabinoid Interactions Mediate Spike-Timing-dependent Potentiation in the Striatum

Dopaminergic inhibition of the inwardly rectifying potassium current in direct pathway medium spiny neurons in normal and parkinsonian striatum

The Effects of Adenosine A2A Receptor Antagonist on the Behavior and the Striatal A2A Receptor,metabotropic Glutamate Receptors Protein Expression in Rats with Levodopa-Induced Dyskinesia

Dissociable Effects of Dopamine on Neuronal Firing Rate and Synchrony in the Dorsal Striatum

Control of Dopamine Signal in High-Order Receptor Complex on Striatal Astrocytes

The D2 Dopamine Receptor Interferes with the Protective Effect of the A(2A) Adenosine Receptor on TDP-43 Mislocalization in Experimental Models of Motor Neuron Degeneration

Nmda Receptor Regulation of Levodopa-Induced Behavior and Changes in Striatal G Protein-Coupled Receptor Kinase 6 and Beta-Arrestin-1 Expression in Parkinsonian Rats

Β2⁎ and Β4⁎ Nicotinic Acetylcholine Receptor Expression Changes with Progressive Parkinsonism in Non-Human Primates

A2A adenosine receptor agonists, antagonists, inverse agonists and partial agonists

Biased Signaling Agonists Promote Distinct Phosphorylation and Conformational States of the Dopamine D3 Receptor

In Vivo Effects of Activation and Blockade of 5-HT(2A/2C) Receptors in the Firing Activity of Pyramidal Neurons of Medial Prefrontal Cortex in a Rodent Model of Parkinson's Disease.

Subunit composition of nicotinic receptors in monkey striatum: effect of treatments with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine or L-DOPA.

Opposite regulation by L-DOPA receptor GPR143 of the long and short forms of the dopamine D2 receptors